Next Generation Human-Derived Blood Replacement
Abstract
Develop, demonstrate in pre-clinical and early-clinical studies, and transition new blood products with increased shelf life and functionality including cold-stored platelets and biopharmaceutical technologies that stop life threatening bleeding, stabilize tissue metabolism, mitigate shock and restore normal blood clotting will improve prompt hemorrhage control and minimize sustainment requirements.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2022
- Source ID
- 01fa11e5af06538df0775f47dc83a9aa